1 Day TEVA 1.11% DJIA 0.78% S&P 500 1.00% Health Care/Life Sciences 66.70% ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price target of $30.00. The company’s shares ...

Teva's long haul to a turnaround of its business has been dealt a blow by the FDA, which has just declined to approve the company's long-acting formulation of schizophrenia drug risperidone. The ...

Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

After hours: January 24 at 7:39:07 p.m. EST ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Gravel shoes are now a well-established segment; long gone are the days of putting up with standard mountain bike shoes. Now most brands have some gravel-specific footwear in their range focusing ...